This article is more than 5 years old. Information may no longer be current.
European Commission approves DuoResp Spiromax for asthma, COPD
Click Here to Manage Email Alerts
The European Commission has approved a multidose dry-powder inhaler for the treatment of patients with asthma and chronic obstructive pulmonary disease, according to a press release.
DuoResp Spiromax (Teva Pharmaceutical Industries) contains budesonide, an inhaled corticosteroid and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta-2-agonist for bronchoconstriction caused by asthma and COPD.
“We are delighted to receive approval for DuoResp Spiromax,” Rob Koremans, MD, president and CEO of Teva Global Specialty Medicines, said in a press release. “This is a major advance in inhalers — the need for more intuitive devices is critical and has been highlighted by health care professionals and patient groups. It is widely accepted that poor or inadequate inhaler technique not only negatively impacts treatment adherence, but means that patients do not obtain the full benefit from their medication.”
Two phase 3 trials comparing the benefits of DuoResp Spiromax and a budesonide/formoterol multi-dose dry powder inhaler are under way in Europe, according to the press release. Data are expected to be released this year.